Table 3.

Cost-Effectiveness of Various Hepatitis C Virus (HCV) Treatment Regimens Worldwide

Treatment/Study	Country	Therapy duration, weeks	Life year gained	Quality-adjusted life year gained
Interferon monotherapy
Sagmeister M, Wong JB, Mullhaupt B, Renner EL100	Switzerland	48	0.71–2.43*	0.77–2.77*
Stein K, Rosenberg W, Wong J101	United Kingdom	24–48**	NA	1.90
Siebert U, Sroczynski G102	Germany	48†	1.27	1.32
Interferon plus ribavirin
Wong JB, Koff RS103	United States	24–48**	1.60	2.40
Sagmeister M, Wong JB, Mullhaupt B, Renner EL100	Switzerland	24	1.47–5.36*	1.61–6.21*
		48	2.57–5.41*	2.77–6.13*
Sennfält K, Reichard O, Hultkrantz R, Wong JB, Jonsson D104	Sweden	24	NA	1.10–4.10*
		48	NA	NA-1.70*
Stein K, Rosenberg W, Wong J101	United Kingdom	24–28**	NA	4.82
Wong JB, Nevens F105	Belgium	24–28*	2.82	3.72
Siebert U, Sroczynski G, Rossol S, et al106	Germany	48†	3.60	3.80
Wong JB, Davis GL, McHutchison JG, Manns MP, Albrecht JK107	United States	12–48‡	3.10	4.00
Siebert U, Sroczynski G, Wasem J, et al108	Germany	24	2.84	2.97
Sroczynski G, Rafetseder O, Jonas S, Siebert U109	Austria	12–48‡	2.5	2.6
Brady B, Siebert U, Sroczynski G, et al110	Canada	12–48‡	2.91	2.11
Peginterferon plus ribavirin
Wong JB, Nevens F105	Belgium	24–48	3.77	4.99
Siebert U, Sroczynski G, Rossol S, et al106	Germany	48†	4.20	4.30
Wong JB, Davis GL, McHutchison JG, Manns MP, Albrecht JK107	United States	12–48‡	3.60–4.00¶	4.60–5.20¶
Sroczynski G, Rafetseder O, Jonas S, Siebert U109	Austria	12–48‡	4.30	4.50
Brady B, Siebert U, Sroczynski G, et al110	Canada	12–48‡	3.90	2.80

^*The range of values in patients with HCV genotype 1 infection and patients with other genotypes.

^**Depending on HCV genotype.

^†48 weeks of treatment for patients who responded to treatment at Week 24.

^‡Depending on HCV genotype infection and early virologic response to treatment.

^¶The range of values in patients with HCV genotype 1 infection and patients with HCV genotype 2 or 3 infection.

Adapted from Sroczynski G, et al.⁶¹